T Lymphocyte Activation Antigen CD80 Market 2021 Share, Growth and Regional Forecast
ReportsWeb.com published “T Lymphocyte Activation Antigen CD80 - Pipeline Review H1 2017” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months.
(EMAILWIRE.COM, October 04, 2017 ) ReportsWeb.com published “T Lymphocyte Activation Antigen CD80 - Pipeline Review H1 2017” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months.
Original Content:
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report T Lymphocyte Activation Antigen CD80 - Pipeline Review, H1 2017, outlays comprehensive information on the T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.
For more information about this report: http://www.reportsweb.com/t-lymphocyte-activation-antigen-cd80-pipeline-review-h1-2017
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Cluster of differentiation 80 or CD80 or B7-1 is a protein found on dendritic cells, activated B cells and monocytes. The activated protein induces T-cell proliferation and cytokine production. T-cell proliferation and cytokine production is induced by the binding of CD28. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 4 and 2 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Musculoskeletal Disorders, Cardiovascular, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders and Ophthalmology which include indications Rheumatoid Arthritis, Autoimmune Disorders, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Alopecia, Breast Cancer, Dermatomyositis, Giant Cell Arteritis, Graft Versus Host Disease (GVHD) , Granulomatosis with Polyangiitis (Wegener Polyangiitis) , Hepatocellular Carcinoma, Juvenile Rheumatoid Arthritis, Lupus Nephritis, Myasthenia Gravis, Nephrotic Syndrome, Polyarticular Juvenile Idiopathic Arthritis (PJIA) , Polymyositis/Idiopathic Inflammatory Myopathy, Primary Biliary Cirrhosis, Psoriasis, Psoriatic Arthritis, Sicca Syndrome (Sjogren) , Systemic Idiopathic Juvenile Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma) , Takayasu Arteritis, Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes) , Uveitis and Vitiligo.
Report Scope
- The report provides a snapshot of the global therapeutic landscape for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)
- The report reviews T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics and enlists all their major and minor projects
- The report assesses T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001834417/sample
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indications, H1 2017
Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by 3SBio Inc, H1 2017
Pipeline by BioAtla LLC, H1 2017
Pipeline by Bristol-Myers Squibb Company, H1 2017
Pipeline by KAHR medical Ltd, H1 2017
Pipeline by MediGene AG, H1 2017
Pipeline by MedImmune LLC, H1 2017
Pipeline by Momenta Pharmaceuticals Inc, H1 2017
Dormant Products, H1 2017
Dormant Products, H1 2017 (Contd..1) , H1 2017
Discontinued Products, H1 2017
List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Top 10 Indications, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
Inquire before Buying at http://www.reportsweb.com/buy&RW0001834417/buy/3500
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
Original Content:
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report T Lymphocyte Activation Antigen CD80 - Pipeline Review, H1 2017, outlays comprehensive information on the T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.
For more information about this report: http://www.reportsweb.com/t-lymphocyte-activation-antigen-cd80-pipeline-review-h1-2017
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Cluster of differentiation 80 or CD80 or B7-1 is a protein found on dendritic cells, activated B cells and monocytes. The activated protein induces T-cell proliferation and cytokine production. T-cell proliferation and cytokine production is induced by the binding of CD28. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 4 and 2 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Musculoskeletal Disorders, Cardiovascular, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders and Ophthalmology which include indications Rheumatoid Arthritis, Autoimmune Disorders, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Alopecia, Breast Cancer, Dermatomyositis, Giant Cell Arteritis, Graft Versus Host Disease (GVHD) , Granulomatosis with Polyangiitis (Wegener Polyangiitis) , Hepatocellular Carcinoma, Juvenile Rheumatoid Arthritis, Lupus Nephritis, Myasthenia Gravis, Nephrotic Syndrome, Polyarticular Juvenile Idiopathic Arthritis (PJIA) , Polymyositis/Idiopathic Inflammatory Myopathy, Primary Biliary Cirrhosis, Psoriasis, Psoriatic Arthritis, Sicca Syndrome (Sjogren) , Systemic Idiopathic Juvenile Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma) , Takayasu Arteritis, Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes) , Uveitis and Vitiligo.
Report Scope
- The report provides a snapshot of the global therapeutic landscape for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)
- The report reviews T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics and enlists all their major and minor projects
- The report assesses T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001834417/sample
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indications, H1 2017
Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by 3SBio Inc, H1 2017
Pipeline by BioAtla LLC, H1 2017
Pipeline by Bristol-Myers Squibb Company, H1 2017
Pipeline by KAHR medical Ltd, H1 2017
Pipeline by MediGene AG, H1 2017
Pipeline by MedImmune LLC, H1 2017
Pipeline by Momenta Pharmaceuticals Inc, H1 2017
Dormant Products, H1 2017
Dormant Products, H1 2017 (Contd..1) , H1 2017
Discontinued Products, H1 2017
List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Top 10 Indications, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
Inquire before Buying at http://www.reportsweb.com/buy&RW0001834417/buy/3500
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results